Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at agilon health (NYSE:AGL) and the best and worst performers in the outpatient & specialty care industry.

Agilon Health’s second quarter was marked by significant beats on both revenue and profitability, but the results did not prevent a notable drop in the company’s share price. Management attributed the quarter’s strong financials to operational improvements, including earlier identification of high-risk conditions and expanded adoption of clinical pathways, especially in chronic heart failure management. CEO Tim O’Rourke emphasized that these changes are structural rather than short-term fixes, n

Revenue hit $1.49 billion as medical margins swung sharply positive.

Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

Boeing upgraded, Under Armour downgraded: Wall Street's top analyst calls

Why agilon health stock is in focus after the latest earnings agilon health (AGL) is back on investors’ radar after second quarter results showed a shift from loss to profit, alongside revenue above market expectations and higher full year revenue guidance for 2026. See our latest analysis for agilon health. The latest quarter has put agilon health back in the spotlight, even as the share price has been volatile. The 1 day share price return is down 19.49% and the 7 day share price return is...

Agilon Health (NYSE:AGL) reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 out

Agilon (AGL) delivered earnings and revenue surprises of +1,633.33% and +3.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Healthcare services company Agilon Health (NYSE:AGL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 7.2% year on year to $1.49 billion. On top of that, next quarter’s revenue guidance ($1.46 billion at the midpoint) was surprisingly good and 3.7% above what analysts were expecting. Its GAAP profit of $1.04 per share was significantly above analysts’ consensus estimates.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Shares of healthcare services company Agilon Health (NYSE:AGL) fell 10.8% in the afternoon session after Citi downgraded the stock's rating from Neutral to Sell, citing valuation concerns. The downgrade followed a massive 650% rally in 2026, which left the stock trading at a 38% premium compared to its peers. Citi noted this valuation was "too rich," especially since the company faced risks as Medicare Advantage plans sought to retain margins heading into 2027. Despite raising the price target f

Autodesk initiated, Norwegian Cruise downgrade: Wall Street's top analyst calls

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.